Nucleic Acid News and Research

RSS

New study reveals cause of chronic inflammation with age

A new study led by researchers at The University of Texas MD Anderson Cancer Center has uncovered a previously unknown connection between nucleic acid structures called R-loops and age-related inflammation – or inflammaging – that could herald new intervention options for chronic inflammation and the subsequent health conditions.

16 Jun 2026

Salt-loaded nanoparticles help deliver fragile gene therapies into cells

Researchers at the University of Houston's College of Pharmacy have discovered an unexpected simple strategy to improve the performance of mRNA vaccines and gene therapeutics: adding salt.

16 Jun 2026

Scientists reveal how cGAS-STING fuels brain inflammation and neurodegeneration

The cGAS-STING pathway is emerging as a key driver of chronic neuroinflammation through its effects on glial activation, neuronal stress, blood-brain barrier integrity, and type I interferon signaling. The review highlights why selective, context-dependent modulation of cGAS-STING could help treat neurodegenerative diseases, while preserving its essential roles in antiviral defense and tumor surveillance.

10 Jun 2026

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Professor Heddle's insights on nanobiology and AI highlight their potential to innovate drug delivery and vaccine development, addressing critical health needs.

9 Jun 2026

Enhancing reproducibility in genomics workflows with magnetic bead-based extraction

In this interview, Dr Dagmara Lewandowska talks about innovations in magnetic bead-based extraction and genomics automation.

From INTEGRA Biosciences 1 Jun 2026

4basebio launches high-performance enzymatic ssDNA platform to accelerate next-generation gene editing

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.

From 4basebio PLC 29 May 2026

One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial

A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced dose-dependent reductions in circulating PCSK9 protein and LDL cholesterol in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.

26 May 2026

Squid™ Full Range Pipette: Reduce pipette changes, bench clutter, and calibration burden

The Squid Full Range Pipette covers 1–1000 µL in one device, reducing pipette changes, bench clutter, calibration burden, and workflow fatigue.

From DeNovix Inc. 22 May 2026

Cell swelling in macrophages may trigger stronger inflammatory immune responses

As part of the body's first line of defense against foreign invaders, macrophages play an integral role in the innate immune system.

7 May 2026

Photodynamic strategies enhance antibacterial performance of titanium orthopedic implants

The increasing global aging population has led to a steady rise in the demand for titanium orthopedic implants.

5 May 2026

UCLA researchers build programmable artificial organelles using RNA

Just as the human body relies on organs such as the heart or liver for essential functions, cells depend on their own tiny organs, or organelles, to carry out vital tasks, including transporting nutrients, removing waste and regulating genetic activity.

30 Apr 2026

Antisense oligonucleotides reverse rare neurodevelopmental disorder in preclinical models

Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related neurodevelopmental disorder using antisense oligonucleotides (ASOs) in preclinical models. ASOs are short synthetic nucleic acid strands that target specific messenger RNA.

22 Apr 2026

Gut microbiome clues may help spot Parkinson’s disease in its earliest phase

Researchers found that a Parkinson’s disease-related gut microbiome pattern appears not only in people with diagnosed Parkinson’s, but also in some non-manifesting GBA1 variant carriers and a subset of healthy individuals. The findings suggest that gut microbiome changes may help flag people who are closer to Parkinson’s disease development, although longitudinal studies are still needed to confirm predictive value.

21 Apr 2026

Nature-inspired vesicles offer new path for precision medicine therapies

A quiet revolution is underway in modern medicine: Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies.

17 Apr 2026

Requests for “unvaccinated” blood lead to delays and patient harm

The trend for unvaccinated blood donations raises concerns about patient safety and resource efficiency, emphasizing the need for better transfusion protocols.

6 Apr 2026

Primerdesign partners with Origin Sciences to create novel rectal mucosal extraction workflow

Primerdesign (part of the Novacyt Group), a company focused on the design, manufacture, validation and supply of nucleic acid extraction and real-time PCR kits, and Origin Sciences (Origin), a company pioneering the detection and diagnosis of gastrointestinal (GI) disease through an unprecedented focus on a unique biospecimen: rectal mucus; today announced a strategic partnership to create a new protocol that optimizes DNA extraction from novel rectal mucosal samples.

From Primerdesign 25 Mar 2026

SonoPIN technology boosts intracellular delivery of large cancer drugs

Engineers at Duke University have demonstrated a technique that uses microbubbles and ultrasound to help relatively large cancer drugs enter tumor cells and cause them to self-destruct.

13 Mar 2026

4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer

4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the promotion of Christine Wolosin to Chief Commercial Officer.

From 4basebio PLC 10 Mar 2026

Nearly 70 weeks after infection, long COVID patients show no detectable inflammation in blood tests

A controlled Norwegian case-control study examined circulating biomarkers of inflammation and neuronal injury in people with long COVID about 69 weeks after infection. The researchers found no significant differences in systemic inflammatory or neuroinjury markers compared with recovered controls after statistical correction.

4 Mar 2026

MERLIN algorithm unlocks immune cell location memory in organs

A new AI-based method reconstructs spatial information about where immune cells were originally located in an organ, even after these cells have been removed from the tissue and analyzed individually.

2 Mar 2026